Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia.

Pedro Abizanda SolerJuan María Calbo MayoMarta Mas RomeroElisa Belén Cortés ZamoraMaría Teresa Tabernero SahuquilloLuis Romero RizosPedro Manuel Sánchez-JuradoGinés Sánchez-NievasCarlos Campayo EscolanoAlba Ochoa SerranoVictoria Sánchez-Flor AlfaroRita López BruCristina Gómez BallesterosDavid Caldevilla BernardoFrancisco Javier Callejas GonzálezFernando Andrés-PretelVolker Martin LauschkeJustin Stebbing

Published in: Journal of the American Geriatrics Society (2021)

Baricitinib is associated with an absolute mortality risk reduction of 18.5% in adults older than 70 years hospitalized with COVID-19 pneumonia.

Keyphrases

coronavirus disease
sars cov
community dwelling
middle aged
physical activity
respiratory syndrome coronavirus
high intensity
risk factors
respiratory failure
community acquired pneumonia
type diabetes